Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on treatments for neurodegenerative and metabolic disorders and alcohol misuse, announced that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. The license permits the sale of Qlarity in Canada with recommended uses including supporting energy production, metabolism, electrolyte balance, mental alertness, cognitive performance, endurance, and fatigue reduction. This regulatory approval marks a significant milestone for the company as it expands its product portfolio into the Canadian market.
Quantum previously licensed a similar product in the United States under the brand name unbuzzd(TM). The company retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc., which markets the OTC version. The agreement also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The Health Canada license for Qlarity underscores the company's ability to navigate regulatory pathways and bring products to market. This development is important as it not only opens a new revenue stream in Canada but also validates the company's product development and regulatory strategy. The approval could enhance investor confidence in Quantum's broader pipeline, including its lead compound Lucid-MS, which is being developed for multiple sclerosis. For more details, the full press release can be accessed at https://ibn.fm/kFwdj.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Investors can find the latest news and updates relating to QNTM at https://ibn.fm/QNTM.
